FORM OF NORTHWEST BIOTHERAPEUTICS, INC. LOAN AGREEMENT and 10% CONVERTIBLE PROMISSORY NOTELoan Agreement • June 7th, 2007 • Northwest Biotherapeutics Inc • Pharmaceutical preparations • Delaware
NORTHWEST BIOTHERAPEUTICS, INC. FORM OF WARRANTWarrant Agreement • June 7th, 2007 • Northwest Biotherapeutics Inc • Pharmaceutical preparations • Delaware
This Certifies That, for value received, Toucan Partners, LLC, with its principal office at 7600 Wisconsin Avenue, Suite 700, Bethesda, MD 20814, and/or its assigns (collectively, the “Holder”), is entitled to subscribe for and purchase from Northwest Biotherapeutics, Inc., a Delaware corporation, with its principal office at 18701 120th Avenue NE, Suite 101, Bothell, Washington 98011 (the “Company”), such number of Exercise Shares as provided herein at the Exercise Price (each subject to adjustment as provided herein). This Warrant is being issued pursuant to the terms of the Recapitalization Agreement, dated as of April 26, 2004, as amended and restated on July 30, 2004, and as further amended from time to time, by and among the Company and Toucan Capital Fund II, L.P. (the “Recapitalization Agreement”).
NORTHWEST BIOTHERAPEUTICS, INC. SERIES A-1 PREFERRED STOCK WARRANTWarrant Agreement • June 7th, 2007 • Northwest Biotherapeutics Inc • Pharmaceutical preparations • Delaware
This Certifies That, for value received, Toucan Capital Fund II, L.P., with its principal office at 7600 Wisconsin Avenue, Suite 700, Bethesda, MD 20814, and/or its designees or assigns (collectively, the “Holder”), is entitled to subscribe for and purchase from Northwest Biotherapeutics, Inc., a Delaware corporation, with its principal office at 18701 120th Avenue, NE, Suite 101, Bothell, Washington 98011 (the “Company”), such number of Exercise Shares as provided herein at the Exercise Price (each subject to adjustment as provided herein). This Warrant is being issued in exchange for Warrant Nos. BW-4 through BW-12, each of which was issued pursuant to the terms of the Recapitalization Agreement, dated April 26, 2004, as amended and restated on July 30, 2004, and as further amended from time to time, by and among the Company and the Holder (the “Recapitalization Agreement”).
